Human noroviruses (HunoVs) are a leading cause of foodborne disease and severe childhood diarrhea, and they cause a majority of the gastroenteritis outbreaks worldwide. However, the development of effective and long-lasting HunoV vaccines and therapeutics has been greatly hindered by their uncultivability. We recently demonstrated that a HunoV replicates in human B cells, and that commensal bacteria serve as a cofactor for this infection. In this protocol, we provide detailed methods for culturing the GII.4-sydney HunoV strain directly in human B cells, and in a coculture system in which the virus must cross a confluent epithelial barrier to access underlying B cells. We also describe methods for bacterial stimulation of HunoV B cell infection and for measuring viral attachment to the surface of B cells. Finally, we highlight variables that contribute to the efficiency of viral replication in this system. Infection assays require 3 d and attachment assays require 3 h. analysis of infection or attachment samples, including rna extraction and rt-qpcr, requires ~6 h.
IntroDuctIon
HuNoVs are globally prevalent pathogens. They are the principal cause of gastroenteritis outbreaks in industrialized and developing nations 1, 2 , causing over 20 million symptomatic infections in the United States each year 3 . HuNoVs are now recognized as the leading cause of severe childhood diarrhea in parts of the world where an effective rotavirus vaccine has been introduced 4, 5 , and they are the most common cause of foodborne disease outbreaks globally 6 . Despite the clinical importance of these viruses, relatively little is known about their pathogenic mechanisms. One of the most notable obstacles to investigating HuNoVs has historically been their uncultivability. Considering the enteric nature of HuNoVs, intestinal epithelial cells (IECs) lining the gut are a hypothesized cellular target. Yet extensive efforts to cultivate HuNoVs in epithelial cells have been thus far unsuccessful [7] [8] [9] [10] , although NoVs can be internalized by IECs and transcytosed across them [11] [12] [13] [14] . The closely related murine NoVs (MuNoVs) are well established to display tropism for macrophages and dendritic cells in vitro and in vivo, yet they do not seem to replicate in epithelial cells [15] [16] [17] . Although efforts to infect primary bloodderived human macrophages and dendritic cells with a HuNoV were unsuccessful 18 , several pieces of data led us to recently test whether B cells represent a novel NoV target cell: viral antigen was visualized in the B cell zones of Peyer's patches in intestinal sections of MuNoV-infected mice 17, 19 ; acute MuNoV titers were lower in B cell-deficient animals compared with wild-type mice 20 ; and viral antigen was detected in intestinal B cells in HuNoVinfected chimpanzees 21 . Indeed, we demonstrated that multiple MuNoV strains and one HuNoV strain infect cultured B cells 22, 23 . Infection of B cells did not result in a detectable loss in cell viability 22, 23 ; this finding was unexpected considering that NoVs are nonenveloped and that MuNoV infection of macrophages and dendritic cells is lytic 15, 22 . Importantly, HuNoV replication in B cells is productive, as evidenced by increases in viral genome copies, translation of viral nonstructural and structural proteins and production of infectious progeny virus 22, 23 . This represents the first cultivation system for a HuNoV. Overall evidence thus suggests that NoVs are transcytosed across the intestinal epithelium where they then access their underlying target immune cells, including innate and adaptive cell types 24 . Here we provide a detailed description of the methods for culturing a HuNoV either in B cells directly or in a coculture system in which the virus must cross a confluent epithelial monolayer to access underlying B cells. A major strength of this assay is its technical simplicity, as it comprises a commonly used cell line maintained in standard medium. A major drawback is the modest level of viral replication achieved in its current state. We also discuss variables influencing the efficiency of HuNoV replication in B cells and the status of reproducibility of this system in other laboratories.
Comparison with other methods
Many groups have unsuccessfully attempted to culture HuNoVs in a variety of cell types, most notably epithelial cells, because this is the first cell type encountered by pathogens that enter the host along mucosal surfaces [7] [8] [9] [10] . One study failed to detect infection of primary human blood-derived macrophages and dendritic cells with a HuNoV 18 in spite of the established tropism of MuNoVs for these cell types 15 . A majority of previous studies focused on one HuNoV genotype (Norwalk virus, a genogroup I, genotype 1 (GI.1) strain) because of the availability of large volumes of Norwalk-positive stool samples, although other genotypes have been tested in more limited analyses 7 . We instead tested a GII. 4 HuNoV strain, specifically GII.4-Sydney 22 . This stool sample was collected from a 69-year-old male passenger presenting with symptoms of HuNoV infection during a cruise ship outbreak in January of 2013. Another major difference between our methodology and all other studies investigating the cultivability of HuNoVs to the best of our knowledge is that we used unfiltered, unprocessed stool as inoculum, whereas other groups filtered virus-positive stool before applying it onto cultured cells and, in many cases, they further purified virions through sucrose cushions or density gradients. This is a major consideration when comparing methodologies on the basis of our finding that commensal bacteria present in unfiltered inoculum serve as cofactors for infection 22, 23 . Our experiments implicate bacterial surface-expressed histo-blood group antigen (HBGA) as the stimulatory factor, as a HBGA-expressing bacteria could fully rescue the infectivity of filtered inoculum, whereas a non-HBGAexpressing bacteria could not; additionally, synthetic HBGA was also able to rescue infectivity 22, 23 . Although the presence of exogenous HBGA facilitated HuNoV attachment to the surface of B cells and infection 22, 23 , HBGA expression is not sufficient for in vitro permissivity considering that HBGAs expressed on IECs do not render the cells susceptible to viral infection 25 . Thus, available data indicate that HuNoVs use HBGAs, possibly as attachment factors, and a yet-to-be-identified B cell receptor for viral entry. It is possible that other attempts to culture HuNoVs were unsuccessful because they focused on cell types not expressing the appropriate receptor and/or because they lacked the appropriate commensal bacterial cofactor for infection. It is also feasible that additional cell types including enterocytes will support HuNoV infection when grown under key (yet elusive) conditions.
Limitations
A limitation of this system is the modest level of viral output achieved, ranging from 0.5 to 3.5 logs in a given experiment (Fig. 1) . Another limitation is the nature of the inoculum used as a source of virus, which is specifically unfiltered fecal material. This complicated matrix probably delivers signals of an indeterminate nature to the B cells that could influence their susceptibility to viral infection, possibly contributing to the experimental variability inherent to the system. Indeed, we have observed an inverse correlation between viral input levels and infection efficiency ( Fig. 1 ) that could be explained by the presence of an inhibitor in the unfiltered stool sample used as a source of virus. An alternative possible explanation is that viral genome replication is masked by high input levels because of a threshold effect in viral replication. Finally, in spite of the technical simplicity of this method, successful replication of a HuNoV in B cells in other laboratories has been proven to be difficult. As a result, we are working closely with several laboratories to identify key variables influencing viral infection efficiency. We have most extensively collaborated with the Vinjé research group at the United States Centers for Disease Control and Prevention (CDC). Although we have yet to achieve successful infections at this location in spite of intensive efforts and many experimental repeats, we have excluded numerous variables that could influence infection efficiency including differences in medium components, tissue culture plasticware, RNA extraction methods and RT-qPCR analysis. We have also excluded user-variability as being a contributing factor, as members of research groups from the CDC, the University of Michigan (Wobus research group) and Erasmus Medical Center (EMC; Koopmans research group) have successfully infected human BJAB cells with the GII.4-Sydney HuNoV strain when performing infections at the University of Florida, where this system was developed (Fig. 2a) , whereas a member of the Karst laboratory (University of Florida) was unsuccessful in infecting BJAB cells at the CDC (data not shown). The research group at EMC has not achieved successful infection at their institute, potentially because of differences in FBS source or virus stock. However, research groups at the University of Michigan (Fig. 2b) and St. Jude Children's Research Hospital (Schultz-Cherry research group; data not shown) have successfully infected BJAB cells with a HuNoV at their own institutions, although infection efficiency at St. Jude's has been variable. We have discovered that the source of FBS in medium can influence viral infection efficiency ( Fig. 2c) , as is true for a variety of other viruses. Empirical evidence suggests that the state of the B cells at the time of viral inoculation is key to achieving successful infection (described in more detail in the protocol).
Applications
Although the HuNoV cell culture system described here is in the initial stages of development and currently supports only modest levels of viral replication, the availability of permissive cells supporting in vitro HuNoV replication has tremendous potential to transform NoV research. Extrapolating to the long and equally challenging history of developing hepatitis C virus (HCV) cell culture systems, the development of first-generation lowefficiency cell culture systems facilitated the identification of both host and viral factors contributing to enhanced HCV replication, and it was directly linked to the development of successful anti-HCV drugs 26 . Moreover, even in its current state, the HuNoV B cell culture system has led to the discovery of a cofactor for viral infection (i.e., commensal bacteria expressing appropriate HBGA glycans), and it has been used to demonstrate the neutralizing activity of a polyclonal anti-capsid antibody 22 .
In addition, because we have developed viral attachment (Box 1) and infection (see PROCEDURE) assays, it should be possible to gain insight into the mechanisms by which antibodies neutralize HuNoVs. Other applications of this first-generation cell culture system include viral receptor identification and testing of putative antiviral compounds for in vitro activity.
Experimental design
Maintenance of B cell lines. The BJAB cell line has been used for a majority of our experiments, and we focus on it exclusively in this protocol. However, we have tested a panel of other human B cell lines and determined that the Raji line (kindly provided by G. McFadden, University of Florida) also supports GII.4-Sydney infection, whereas the Namalwa and HuNS1 lines (also provided by G. McFadden) do not support infection to appreciable levels ( Fig. 3) . We obtained the BJAB cell line from R. 3. Quick-thaw the virus-positive stool sample in a 37 °C water bath, dilute it to 1:10 in complete RPMI and immediately place it on ice. 4. Add 2 × 10 5 BJAB cells and 1.5 × 10 6 viral-genome copies of diluted stool sample into each microcentrifuge tube, bring it up to a total volume of 360 µl using chilled complete RPMI, mix briefly by pipetting and immediately place the tube on ice.
 crItIcal step The samples should be kept on ice for the entirety of the experiment. 5. Add 120 µl of the virus:cell mixture into three wells of the prechilled 48-well plate and incubate it at 4 °C for 1 h. 6. Transfer the contents of one well into a microcentrifuge tube, add 1 ml of TRIzol and store it at −80 °C for future RNA extraction according to the manufacturer's instruction, as described in PROCEDURE Step 2A(i) (this sample will allow you to confirm the input number of viral genomes). 7. Transfer the contents of the other two wells into two microcentrifuge tubes, and centrifuge at 730g for 7.5 min at 4 °C. 8. Discard the supernatant and resuspend the pellet in 200 µl of chilled 1× PBS; mix by pipetting. 9. Wash the cells two more times, as described in steps 7 and 8. 10. After the third wash, add 1 ml of TRIzol to each supernatant and store it at −80 °C for future RNA extraction according to the manufacturer's instructions, as described in PROCEDURE Step 2A(i) (these samples will contain only genomes associated with virus attached to the B cells). 
Controls. For all infection and attachment experiments, mockinoculated cells (i.e., prepared identically to HuNoV-infected cells but inoculated with media only) should be tested in parallel to
HuNoV-infected cells to serve as a negative control. For all experiments supplementing filtered stool with a stimulatory factor such as appropriate bacteria, filtered stool in the absence of the stimulatory factor should be included as a negative control and unfiltered HuNoV-positive stool should be included as a positive control. 
MaterIals

REAGENTS
Virus-positive stool sample ! cautIon HuNoVs are biosafety level 2 (BSL2) pathogens, so standard BSL2 practices should be adhered to strictly whenever you are working with live virus. Acquisition of virus-positive stool samples from infected subjects should only be performed in accordance with a protocol approved by an appropriate institutional review board. • , split a BJAB culture 1:4 in a six-well dish and bring it to a total volume of 2 ml; incubate the plate at 5% CO 2 in a 37 °C incubator for 4 d. (ii) On 0 d.p.i., quick-thaw the virus-positive stool sample in a 37 °C water bath, dilute it 1:10 in complete RPMI and immediately place it on ice.  crItIcal step Virus-positive stool samples should be divided into single-use aliquots (aliquot volume will need to be determined empirically for each stool sample) and frozen at −80 °C to avoid freezing/thawing the virus. (iii) Transfer 1.3 × 10 5 BJAB cells (determined by counting cells using a hemocytometer) into a microcentrifuge tube.
 crItIcal step The cell density and state of the cells at the time of inoculation influences their susceptibility to HuNoV infection; confirm that the BJAB culture is replicating at an appropriate doubling time (33 h) and that large clumps have formed (Fig. 4) . (iv) Add 10 4 -10 6 viral genome copies of the stool sample to the B cells and mix briefly by pipetting. Viral genome concentration in a stool sample should be determined before use in infection assays by using the RNA extraction and RT-qPCR protocols outlined in Step 2.  crItIcal step The amount of input virus affects the efficiency of infection (see Fig. 1 , explained further in the INTRODUCTION). (v) Bring the total volume up to 100 µl using complete RPMI. Incubate the mixture for 2 h at 5% CO 2 in a 37 °C incubator.  crItIcal step Volume is reduced by filtration, so filter 1.5-2 times the necessary final volume of stool needed for the experiment.
(x) Aliquot 20 µl of heat-inactivated bacteria and 10 4 -10 6 viral genome copies of filtered stool sample (genome copy concentration of the virus-positive stool sample used as a source of virus should be determined before use in infection assays using the RNA extraction and RT-qPCR protocols outlined in Step 2) into each microcentrifuge tube, and incubate the tubes at 5% CO 2 in a 37 °C incubator for 1 h. (xi) Add 1.3 × 10 5 BJABs to the bacteria-virus mixture in the microcentrifuge tube from Step 1B(x), and bring the total volume up to 100 µl using complete RPMI; incubate for 2 h at 5% CO 2 in a 37 °C incubator. Nuclease-free water 9.5 µl Box 1, 2 h Box 2, 13 h
Step 2A(iii), RT-qPCR reaction:1.5 h
Step 2A (iv) , standard curve preparation: 8 h
Step 2B(i), RNA extraction: 2.5 h
Step 2B(ii), cDNA synthesis: 2 h
Step 2B(iii), qPCR setup: 45 min
Step 2B (iv) There is considerable variability in the efficiency of infection within and between experiments, ranging from 0.5-to 3.5-log fold increases in genome copy number (Fig. 1) . Thus, we recommend averaging results from at least triplicate reactions per condition in a given experiment and a minimum of two experimental replicates before applying statistical tests. On the basis of our published findings 22, 23 , filtration of the virus-positive stool sample through a 0.22-µm membrane should prevent viral genome replication, and preincubation of filtered stool inoculum with appropriate bacteria should fully restore infectivity. We have also demonstrated that B cells cultured in the basal chamber underlying a confluent epithelial monolayer will support HuNoV infection when virus inoculum is applied to the apical supernatant 22, 23 ; B cell infection in this context is also filtration sensitive, and it can be rescued by preincubation of filtered stool inoculum with heat-killed E. cloacae (unpublished results, Karst laboratory). We routinely analyze B cell attachment data as the percentage of viral genomes associated with B cells after washing compared with viral genomes in the unwashed replicate sample. This percentage is typically ~10-50% for unfiltered virus-positive stool inoculum and 1% for filtered inoculum.
